J&J’s first-quarter profit beats estimates even as Stelara sales disappoint
CTV News
—
Johnson & Johnson beat first-quarter earnings expectations on Tuesday and raised its full-year forecast, as strong demand for cancer drug Darzalex and psoriasis treatment Tremfya more than offset a steep falloff in sales of its blockbuster autoimmune drug Stelara.
- J&J’s First-Quarter Sales Grow on Cancer-Drug Strength Wall Street Journal —
- J&J’s first-quarter profit beats estimates even as Stelara sales disappoint The Globe and Mail —
- Johnson & Johnson Non-GAAP EPS of $2.70 beats by $0.02, revenue of $24.06B beats by $450M Seeking Alpha —
- Earnings Snapshot: Johnson & Johnson tops Q1 expectations; boosts full-year outlook and increases quarterly dividend Seeking Alpha —
- Johnson & Johnson in charts: Q1 Innovative Medicine rises 11.2% as DARZALEX leads growth Seeking Alpha —